PreciseDx to Attend the 2024 FLASCO Oncology Business Summit & Spring Session
NEW YORK, May 1, 2024 – PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced their attendance at the 2024 FLASCO Oncology Business Summit & Spring Session in Kissimmee, FL.
Ted Diehl, Vice President of Commercial Development, will be available for an in-depth conversation on the latest advancements at PreciseDx. Specifically, he can discuss how pioneering solutions, such as PreciseBreast™, are utilized by comprehensive breast programs today.
WHO: PreciseDx – A FLASCO Corporate Gold Member
WHAT: Join PreciseDx at the 2024 FLASCO Oncology Business Summit & Spring Session to engage and collaborate with many oncology opinion leaders in Florida.
WHEN: May 4-5, 2024
WHERE: Gaylord Palms Resort & Convention Center Kissimmee, FL
MEDIA: PreciseDx is available for in-person briefings by request via email to precisedx@0to5.com.
About PreciseDx®
PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum. To learn more about PreciseDx, visit https://precisedx.ai
About PreciseBreast™
PreciseBreast™ is an early-stage invasive breast cancer risk assessment, independent of HER2, hormone, and node status. The AI-powered test utilizes standard H&E pathology slide images. Leveraging millions of data points, PreciseBreast™ analyzes, correlates, and quantifies those critical features that predict breast cancer recurrence and delivers a Risk of Recurrence Score. The test meets the rigorous Clinical Laboratory Improvement Amendments (CLIA) standards and has passed the Clinical Laboratory Evaluation Program (CLEP) Assay Validation Review by the New York State Department of Health (NYSDOH). PDxBR will be available worldwide under the brand name of PreciseBreast™. For more information, please contact precisebreast@precisedx.ai.